These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 11145916)

  • 1. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice.
    Revaz V; Benyacoub J; Kast WM; Schiller JT; De Grandi P; Nardelli-Haefliger D
    Virology; 2001 Jan; 279(1):354-60. PubMed ID: 11145916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants.
    Revaz V; Zurbriggen R; Moser C; Schiller JT; Ponci F; Bobst M; Nardelli-Haefliger D
    Antiviral Res; 2007 Oct; 76(1):75-85. PubMed ID: 17617476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice.
    Nardelli-Haefliger D; Roden RB; Benyacoub J; Sahli R; Kraehenbuhl JP; Schiller JT; Lachat P; Potts A; De Grandi P
    Infect Immun; 1997 Aug; 65(8):3328-36. PubMed ID: 9234794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine.
    Nardelli-Haefliger D; Lurati F; Wirthner D; Spertini F; Schiller JT; Lowy DR; Ponci F; De Grandi P
    Vaccine; 2005 May; 23(28):3634-41. PubMed ID: 15882523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines.
    Da Silva DM; Pastrana DV; Schiller JT; Kast WM
    Virology; 2001 Nov; 290(2):350-60. PubMed ID: 11883199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice.
    Liu XS; Abdul-Jabbar I; Qi YM; Frazer IH; Zhou J
    Virology; 1998 Dec; 252(1):39-45. PubMed ID: 9875315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses.
    Báez-Astúa A; Herráez-Hernández E; Garbi N; Pasolli HA; Juárez V; Zur Hausen H; Cid-Arregui A
    J Virol; 2005 Oct; 79(20):12807-17. PubMed ID: 16188983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human papillomavirus vaccines.
    Breitburd F; Coursaget P
    Semin Cancer Biol; 1999 Dec; 9(6):431-44. PubMed ID: 10712890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16.
    Pastrana DV; Vass WC; Lowy DR; Schiller JT
    Virology; 2001 Jan; 279(1):361-9. PubMed ID: 11145917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.
    Daemen T; Pries F; Bungener L; Kraak M; Regts J; Wilschut J
    Gene Ther; 2000 Nov; 7(21):1859-66. PubMed ID: 11110419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1.
    Baud D; Ponci F; Bobst M; De Grandi P; Nardelli-Haefliger D
    J Virol; 2004 Dec; 78(23):12901-9. PubMed ID: 15542642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Papillomavirus virus-like particles as anticancer vaccines.
    Da Silva DM; Velders MP; Rudolf MP; Schiller JT; Kast WM
    Curr Opin Mol Ther; 1999 Feb; 1(1):82-8. PubMed ID: 11249689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
    Pinto LA; Edwards J; Castle PE; Harro CD; Lowy DR; Schiller JT; Wallace D; Kopp W; Adelsberger JW; Baseler MW; Berzofsky JA; Hildesheim A
    J Infect Dis; 2003 Jul; 188(2):327-38. PubMed ID: 12854090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization.
    Kirnbauer R; Chandrachud LM; O'Neil BW; Wagner ER; Grindlay GJ; Armstrong A; McGarvie GM; Schiller JT; Lowy DR; Campo MS
    Virology; 1996 May; 219(1):37-44. PubMed ID: 8623552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression of the human papillomavirus type 16L/E7 fusion protein in E. coli and observation of its immunogenicity in mice].
    Tian HW; Ye ZM; Lu ZH; Jao R; Bian T; Zhao L; Ruan L
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Jun; 20(2):33-7. PubMed ID: 16816859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection.
    Cheung YK; Cheng SC; Sin FW; Xie Y
    Vaccine; 2004 Dec; 23(5):629-38. PubMed ID: 15542183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer.
    Brown DR; Bryan JT; Schroeder JM; Robinson TS; Fife KH; Wheeler CM; Barr E; Smith PR; Chiacchierini L; DiCello A; Jansen KU
    J Infect Dis; 2001 Nov; 184(9):1183-6. PubMed ID: 11598842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The nature of the attenuation of Salmonella typhimurium strains expressing human papillomavirus type 16 virus-like particles determines the systemic and mucosal antibody responses in nasally immunized mice.
    Benyacoub J; Hopkins S; Potts A; Kelly S; Kraehenbuhl JP; Curtiss R; De Grandi P; Nardelli-Haefliger D
    Infect Immun; 1999 Jul; 67(7):3674-9. PubMed ID: 10377159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway.
    Peng S; Frazer IH; Fernando GJ; Zhou J
    Virology; 1998 Jan; 240(1):147-57. PubMed ID: 9448699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
    Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.